A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MEGF0444A, Administered Intravenously to Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 26 Nov 2014
At a glance
- Drugs Parsatuzumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Genentech
- 08 May 2012 Actual end date Oct 2011 added as reported by ClinicalTrials.gov.
- 08 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Aug 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.